Key result
Krakow DCM Risk Score identifies high-risk patients with ~237% higher mortality.
Why the study?
Dilated cardiomyopathy carries high mortality and establishing prognosis is necessary for appropriate heart failure management, but no validated tools have been available for this population.
Does the Krakow DCM Risk Score accurately predict mortality in patients with dilated cardiomyopathy?
Cohort (n=735)
Does the Krakow DCM Risk Score accurately predict mortality in patients with dilated cardiomyopathy?
Effect estimate: HR 3.37 (95% CI 1.88-6.05)
Absolute Event Rate: 42.6% vs 8.3%
p-value: p=< 0.0001
The Krakow DCM Risk Score is a validated prognostic tool that accurately identifies high-risk patients with dilated cardiomyopathy based on a 2-year mortality risk >6%.
May aid DCM mortality risk stratification; leaves open prospective validation before routine use.
Background: One of the most common causes of heart failure is dilated cardiomyopathy (DCM). In DCM, the mortality risk is high and reaches approximately 20% in 5 years. A patient’s prognosis should be established for appropriate HF management. However, so far, no validated tools have been available for the DCM population. Methods: The study population consisted of 735 DCM patients: 406 from the derivation cohort (previously described) and 329 from the validation cohort (from 2009 to 2020, with outcome data after a mean of 42 months). For each DCM patient, the individual mortality risk was calculated based on the Krakow DCM Risk Score. Results: During follow-up, 49 (15%) patients of the validation cohort died. They had shown significantly higher calculated 1-to-5-year mortality risks. The Krakow DCM Risk Score yielded good discrimination in terms of overall mortality risk, with an AUC of 0.704–0.765. Based on a 2-year mortality risk, patients were divided into non-high (≤6%) and high (>6%) mortality risk groups. The observed mortality rates were 8.3% (n = 44) vs. 42.6% (n = 75), respectively (HR 3.37; 95%CI 1.88–6.05; p < 0.0001). Conclusions: The Krakow DCM Risk Score was found to have good predictive accuracy. The 2-year mortality risk > 6% has good discrimination for the identification of high-risk patients and can be applied in everyday practice.
No takes yet. Share an insight, caveat, or question.
Dziewięcka et al. (2022) conducted a cohort in Dilated cardiomyopathy (DCM) (n=735). Krakow DCM Risk Score vs. Non-high risk (≤6% 2-year mortality risk) was evaluated on Mortality (HR 3.37, 95% CI 1.88-6.05, p=< 0.0001). The Krakow DCM Risk Score effectively identified high-risk patients, who had significantly higher mortality than non-high-risk patients (42.6% vs 8.3%; HR 3.37; 95% CI 1.88-6.05; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: